Shenzhen Xinlitai Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") and all members of the board of directors guarantee that the information disclosed is true, accurate, and complete, without any false records, misleading statements, or major omissions.
On May 29, 2026, the Company held the 19th meeting of the 6th board of directors, where the proposal for the share buyback was approved. This proposal falls within the board's approval authority and does not require submission to the shareholders' meeting for deliberation. (For specific details, please refer to the announcement titled "Announcement on the Share Buyback Plan" and the "Resolution Announcement of the 19th Meeting of the 6th Board of Directors" published on June 2, 2026, on the Giant Tide Information Network at www.cninfo.com.cn.)